tiprankstipranks
Trending News
More News >
Clinical Laserthermia Systems AB Class B (SE:CLS.B)
:CLS.B
Advertisement

Clinical Laserthermia Systems AB Class B (CLS.B) AI Stock Analysis

Compare
0 Followers

Top Page

SE:CLS.B

Clinical Laserthermia Systems AB Class B

(Frankfurt:CLS.B)

Rating:53Neutral
Price Target:
kr6.50
▲(38.30%Upside)
The stock score reflects a mix of robust revenue growth and strong technical momentum countered by significant profitability challenges and negative valuation metrics. The company's financial performance highlights the need for improved margins and sustainable cash flow, while technical analysis suggests potential for short-term gains despite valuation concerns.

Clinical Laserthermia Systems AB Class B (CLS.B) vs. iShares MSCI Sweden ETF (EWD)

Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model

Company DescriptionClinical Laserthermia Systems AB Class B (CLS.B) is a Swedish medical technology company specializing in innovative cancer treatment solutions. The company operates in the healthcare sector and is focused on developing and commercializing advanced laser-based systems for minimally invasive thermal treatment of cancerous tumors. CLS.B's core product, the TRANBERG® Thermal Therapy System, employs laser-induced thermotherapy (LITT) to target and destroy cancer cells while preserving surrounding healthy tissue, offering a promising alternative to traditional surgical methods.
How the Company Makes MoneyClinical Laserthermia Systems AB makes money primarily through the sale and distribution of its TRANBERG® Thermal Therapy System and related consumables. Revenue is generated from direct sales to hospitals and clinics, as well as through partnerships with medical distributors and healthcare providers. The company may also earn income from licensing agreements or collaborations with research institutions and medical technology companies. Additionally, ongoing customer support, training services, and maintenance contracts provide recurring revenue streams. Strategic partnerships and clinical trials contribute to the company's growth by expanding its market reach and validating the efficacy of its technology.

Clinical Laserthermia Systems AB Class B Financial Statement Overview

Summary
Clinical Laserthermia Systems AB Class B is experiencing robust revenue growth but continues to face profitability challenges with consistent losses. The balance sheet is strong with low leverage, but cash flow issues persist due to negative free cash flow, highlighting a dependency on external financing. The company needs to focus on cost management to improve margins and achieve sustainable profitability.
Income Statement
25
Negative
The company has shown significant revenue growth from 2023 to 2024, with a growth rate of approximately 127%. However, the company continues to operate at a loss with negative net income and EBIT margins. The gross profit margin has improved but remains unsatisfactory due to high operational costs leading to negative profits.
Balance Sheet
30
Negative
The company has a strong equity position with a high equity ratio of around 87.5% as of 2024. The debt-to-equity ratio is very low, indicating low leverage. However, the company has consistently negative net income, impacting its return on equity, which is currently negative.
Cash Flow
20
Very Negative
The company faces challenges in generating positive cash flows with operating cash flow at zero and negative free cash flow in 2024. The financing cash flow is positive due to significant financing activities, reflecting reliance on external funding.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue18.78M8.27M6.27M2.25M1.33M
Gross Profit10.42M3.00M-2.79M-3.63M876.00K
EBITDA-44.76M-68.41M-57.84M-54.95M-51.61M
Net Income-47.62M-79.79M-70.66M-63.62M-57.94M
Balance Sheet
Total Assets78.56M57.73M49.51M66.74M44.40M
Cash, Cash Equivalents and Short-Term Investments22.51M15.33M10.59M31.17M11.87M
Total Debt224.00K454.00K30.68M273.50K673.50K
Total Liabilities12.88M14.20M41.64M45.55M30.47M
Stockholders Equity68.72M45.77M9.22M21.79M13.93M
Cash Flow
Free Cash Flow-58.92M-71.95M-71.25M-66.73M-55.76M
Operating Cash Flow-56.45M-66.45M-70.69M-66.17M-55.41M
Investing Cash Flow-7.47M-5.50M-886.00K-408.00K-508.00K
Financing Cash Flow71.10M76.69M61.84M85.88M62.02M

Clinical Laserthermia Systems AB Class B Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.70
Price Trends
50DMA
3.33
Positive
100DMA
3.16
Positive
200DMA
3.63
Positive
Market Momentum
MACD
0.76
Negative
RSI
67.47
Neutral
STOCH
69.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Positive. The current price of 4.7 is above the 20-day moving average (MA) of 4.09, above the 50-day MA of 3.33, and above the 200-day MA of 3.63, indicating a bullish trend. The MACD of 0.76 indicates Negative momentum. The RSI at 67.47 is Neutral, neither overbought nor oversold. The STOCH value of 69.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CLS.B.

Clinical Laserthermia Systems AB Class B Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
kr11.14M
96.10%94.79%
53
Neutral
kr154.77M-79.12%86.02%93.34%
52
Neutral
kr5.59B10.05-63.86%2.01%27.11%26.73%
39
Underperform
kr67.75M-20.45%-10.85%
37
Underperform
kr84.60M-51.52%955.20%47.31%
33
Underperform
kr49.44M
-63.52%93.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:CLS.B
Clinical Laserthermia Systems AB Class B
6.07
0.65
12.01%
SE:LXB
Luxbright AB
0.65
-0.28
-30.11%
SE:QLIFE
Qlife Holding AB
3.96
2.34
145.20%
SE:S2M
S2Medical AB Class B
0.01
-0.02
-59.38%
SE:SPEC
SpectraCure AB
0.16
-0.86
-83.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 29, 2025